These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 14767592)

  • 21. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epidemiology and outcome of HIV-infected patients admitted to the ICU in the current highly active antiretroviral therapy era.
    Vidal-Cortés P; Álvarez-Rocha LA; Fernández-Ugidos P; Pérez-Veloso MA; Suárez-Paul IM; Virgós-Pedreira A; Pértega-Díaz S; Castro-Iglesias ÁC
    Med Intensiva (Engl Ed); 2020; 44(5):283-293. PubMed ID: 30971339
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epidemiologic changes in bacteremic pneumococcal disease in patients with human immunodeficiency virus in the era of highly active antiretroviral therapy.
    Grau I; Pallares R; Tubau F; Schulze MH; Llopis F; Podzamczer D; Liñares J; Gudiol F;
    Arch Intern Med; 2005 Jul; 165(13):1533-40. PubMed ID: 16009870
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Short- and long-term outcomes of HIV-infected patients admitted to the intensive care unit: impact of antiretroviral therapy and immunovirological status.
    Morquin D; Le Moing V; Mura T; Makinson A; Klouche K; Jonquet O; Reynes J; Corne P
    Ann Intensive Care; 2012 Jul; 2(1):25. PubMed ID: 22762133
    [TBL] [Abstract][Full Text] [Related]  

  • 25. AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy.
    Lim ST; Karim R; Nathwani BN; Tulpule A; Espina B; Levine AM
    J Clin Oncol; 2005 Jul; 23(19):4430-8. PubMed ID: 15883411
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcomes for critically ill patients with HIV and severe sepsis in the era of highly active antiretroviral therapy.
    Greenberg JA; Lennox JL; Martin GS
    J Crit Care; 2012 Feb; 27(1):51-7. PubMed ID: 22033058
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term HIV/AIDS survival estimation in the highly active antiretroviral therapy era.
    King JT; Justice AC; Roberts MS; Chang CC; Fusco JS;
    Med Decis Making; 2003; 23(1):9-20. PubMed ID: 12583451
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Time to viral load suppression in antiretroviral-naive and -experienced HIV-infected pregnant women on highly active antiretroviral therapy: implications for pregnant women presenting late in gestation.
    Aziz N; Sokoloff A; Kornak J; Leva NV; Mendiola ML; Levison J; Feakins C; Shannon M; Cohan D
    BJOG; 2013 Nov; 120(12):1534-47. PubMed ID: 23924192
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Survival trends in critically ill HIV-infected patients in the highly active antiretroviral therapy era.
    Coquet I; Pavie J; Palmer P; Barbier F; Legriel S; Mayaux J; Molina JM; Schlemmer B; Azoulay E
    Crit Care; 2010; 14(3):R107. PubMed ID: 20534139
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incidence and prognosis of CMV disease in HIV-infected patients before and after introduction of combination antiretroviral therapy.
    Salzberger B; Hartmann P; Hanses F; Uyanik B; Cornely OA; Wöhrmann A; Fätkenheuer G
    Infection; 2005 Oct; 33(5-6):345-9. PubMed ID: 16258865
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A prospective study on the outcome of human immunodeficiency virus-infected patients requiring mechanical ventilation in a high-burden setting.
    Balkema CA; Irusen EM; Taljaard JJ; Zeier MD; Koegelenberg CF
    QJM; 2016 Jan; 109(1):35-40. PubMed ID: 25979269
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Survival in HIV-infected patients is associated with hepatitis C virus infection and injecting drug use since the use of highly active antiretroviral therapy in the Lyon observational database.
    Voirin N; Trépo C; Miailhes P; Touraine JL; Chidiac C; Peyramond D; Livrozet JM; Ritter J; Chevallier P; Fabry J; Allard R; Vanhems P
    J Viral Hepat; 2004 Nov; 11(6):559-62. PubMed ID: 15500557
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lung cancer in HIV positive patients: the GICAT experience.
    Bearz A; Vaccher E; Martellotta F; Spina M; Talamini R; Lleshi A; Cacopardo B; Nunnari G; Berretta M; Tirelli U;
    Eur Rev Med Pharmacol Sci; 2014; 18(4):500-8. PubMed ID: 24610616
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The impact of HAART on the respiratory complications of HIV infection: longitudinal trends in the MACS and WIHS cohorts.
    Gingo MR; Balasubramani GK; Kingsley L; Rinaldo CR; Alden CB; Detels R; Greenblatt RM; Hessol NA; Holman S; Huang L; Kleerup EC; Phair J; Sutton SH; Seaberg EC; Margolick JB; Wisniewski SR; Morris A
    PLoS One; 2013; 8(3):e58812. PubMed ID: 23554932
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Survival of HIV-infected injection drug users (IDUs) in the highly active antiretroviral therapy era, relative to sex- and age-specific survival of HIV-uninfected IDUs.
    Muga R; Langohr K; Tor J; Sanvisens A; Serra I; Rey-Joly C; Muñoz A
    Clin Infect Dis; 2007 Aug; 45(3):370-6. PubMed ID: 17599317
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of highly active antiretroviral therapy on the morbidity and mortality in Spanish human immunodeficiency virus-infected children.
    Sánchez JM; Ramos Amador JT; Fernández de Miguel S; González Tomée MI; Rojo Conejo P; Ferrnado Vivas P; Clemente Vivas J; Ruiz Contreras J; Nogales Espert A
    Pediatr Infect Dis J; 2003 Oct; 22(10):863-7. PubMed ID: 14551485
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improved survival with highly active antiretroviral therapy in HIV-infected patients with severe Pneumocystis carinii pneumonia.
    Morris A; Wachter RM; Luce J; Turner J; Huang L
    AIDS; 2003 Jan; 17(1):73-80. PubMed ID: 12478071
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic factors in HIV-related diffuse large-cell lymphoma: before versus after highly active antiretroviral therapy.
    Lim ST; Karim R; Tulpule A; Nathwani BN; Levine AM
    J Clin Oncol; 2005 Nov; 23(33):8477-82. PubMed ID: 16230675
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Changes in the pattern of respiratory diseases necessitating hospitalization of HIV-infected patients since the advent of highly active antiretroviral therapy.
    Dufour V; Cadranel J; Wislez M; Lavole A; Bergot E; Parrot A; Rufat P; Mayaud C
    Lung; 2004; 182(6):331-41. PubMed ID: 15765925
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association between Highly Active Antiretroviral Therapy and Type of Infectious Respiratory Disease and All-Cause In-Hospital Mortality in Patients with HIV/AIDS: A Case Series.
    Báez-Saldaña R; Villafuerte-García A; Cruz-Hervert P; Delgado-Sánchez G; Ferreyra-Reyes L; Ferreira-Guerrero E; Mongua-Rodríguez N; Montero-Campos R; Melchor-Romero A; García-García L
    PLoS One; 2015; 10(9):e0138115. PubMed ID: 26379281
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.